Zoe M Weinstein1, Gabriela Gryczynski2, Debbie M Cheng3, Emily Quinn4, David Hui5, Hyunjoong W Kim5, Colleen Labelle6, Jeffrey H Samet7. 1. Boston University School of Medicine/Boston Medical Center, Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, 801 Massachusetts Avenue, 2nd Floor, Boston, MA, 02118, United States. Electronic address: zoe.weinstein@bmc.org. 2. Kaiser Permanente, 2238 Geary Blvd, San Francisco, CA, 94115, United States. 3. Boston University School of Public Health, Department of Biostatistics, 801 Massachusetts Avenue, 3rd Floor, Boston, MA, 02118, United States. 4. Boston University School of Public Health, Biostatistics and Epidemiology Data Analytics Center, 85 East Newton St, M921, Boston, MA, 02118, United States. 5. Boston University School of Medicine, 72 East Concord St., Boston, MA, 02118, United States. 6. Boston University School of Medicine/Boston Medical Center, Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, 801 Massachusetts Avenue, 2nd Floor, Boston, MA, 02118, United States. 7. Boston University School of Medicine/Boston Medical Center, Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, 801 Massachusetts Avenue, 2nd Floor, Boston, MA, 02118, United States; Boston University School of Public Health, Department of Community Health Sciences, 801 Massachusetts Avenue, 2nd Floor, Boston, MA, 02118, United States.
Abstract
BACKGROUND: Guidelines recommend long-term treatment for opioid use disorder including the use of buprenorphine; however, many patients desire to eventually taper off. This study examines the prevalence and patient characteristics of patients that voluntarily taper off buprenorphine. METHODS: This is a 12-year retrospective cohort study of adults on buprenorphine in a large urban safety-net primary care practice. The primary outcome was completion of a voluntary buprenorphine taper, which was further characterized as a medically supervised or unsupervised taper. The secondary outcome was re-engagement in care after taper. Descriptive statistics and estimated proportions of both taper completion and re-engagement in treatment were calculated using Kaplan-Meier estimates. RESULTS: The study sample included 1308 patients with a median follow-up time of 316 days; 48 patients were observed to taper off buprenorphine during the study period, with an estimated proportion of 15% (95%CI: 10%-21%) based on Kaplan Meier analyses. Less than half of the tapers, 45.8% (22/48), were medically supervised. Thirteen of the 48 patients subsequently, re-engaged in buprenorphine treatment (estimated proportion 61%, 95%CI: 27%-96%), based on Kaplan-Meier analyses with median follow-up time of 490 days. DISCUSSION: Despite the fact that many patients desire to discontinue buprenorphine, a minority had a documented taper. Among those who tapered, more than half did so unsupervised by the clinic and a majority of those who tapered off returned to buprenorphine treatment within two years. As many patients are unable to successfully taper off buprenorphine, the medical community must work to address any barriers to long-term maintenance.
BACKGROUND: Guidelines recommend long-term treatment for opioid use disorder including the use of buprenorphine; however, many patients desire to eventually taper off. This study examines the prevalence and patient characteristics of patients that voluntarily taper off buprenorphine. METHODS: This is a 12-year retrospective cohort study of adults on buprenorphine in a large urban safety-net primary care practice. The primary outcome was completion of a voluntary buprenorphine taper, which was further characterized as a medically supervised or unsupervised taper. The secondary outcome was re-engagement in care after taper. Descriptive statistics and estimated proportions of both taper completion and re-engagement in treatment were calculated using Kaplan-Meier estimates. RESULTS: The study sample included 1308 patients with a median follow-up time of 316 days; 48 patients were observed to taper off buprenorphine during the study period, with an estimated proportion of 15% (95%CI: 10%-21%) based on Kaplan Meier analyses. Less than half of the tapers, 45.8% (22/48), were medically supervised. Thirteen of the 48 patients subsequently, re-engaged in buprenorphine treatment (estimated proportion 61%, 95%CI: 27%-96%), based on Kaplan-Meier analyses with median follow-up time of 490 days. DISCUSSION: Despite the fact that many patients desire to discontinue buprenorphine, a minority had a documented taper. Among those who tapered, more than half did so unsupervised by the clinic and a majority of those who tapered off returned to buprenorphine treatment within two years. As many patients are unable to successfully taper off buprenorphine, the medical community must work to address any barriers to long-term maintenance.
Authors: Bohdan Nosyk; Huiying Sun; Elizabeth Evans; David C Marsh; M Douglas Anglin; Yih-Ing Hser; Aslam H Anis Journal: Addiction Date: 2012-05-08 Impact factor: 6.526
Authors: Bruce R Schackman; Jared A Leff; Daniel Polsky; Brent A Moore; David A Fiellin Journal: J Gen Intern Med Date: 2012-01-04 Impact factor: 5.128
Authors: Mark L Kraus; Daniel P Alford; Margaret M Kotz; Petros Levounis; Todd W Mandell; Marjorie Meyer; Edwin A Salsitz; Norman Wetterau; Stephen A Wyatt Journal: J Addict Med Date: 2011-12 Impact factor: 3.702
Authors: Stacey C Sigmon; Kelly E Dunn; Kathryn Saulsgiver; Mollie E Patrick; Gary J Badger; Sarah H Heil; John R Brooklyn; Stephen T Higgins Journal: JAMA Psychiatry Date: 2013-12 Impact factor: 21.596
Authors: Paolo Mannelli; Ashwin A Patkar; Kathi Peindl; David A Gorelick; Li-Tzy Wu; Edward Gottheil Journal: Addict Biol Date: 2008-08-19 Impact factor: 4.280
Authors: Michael D Stein; Micah T Conti; Debra S Herman; Bradley J Anderson; Genie L Bailey; Donnell Van Noppen; Ana M Abrantes Journal: Am J Addict Date: 2019-04-16
Authors: Christine M Gunn; Ariel Maschke; Miriam Harris; Samantha F Schoenberger; Spoorthi Sampath; Alexander Y Walley; Sarah M Bagley Journal: Addiction Date: 2020-11-26 Impact factor: 6.526
Authors: William C Becker; Erin E Krebs; Sara N Edmond; Lewei A Lin; Mark D Sullivan; Roger D Weiss; Adam J Gordon Journal: J Gen Intern Med Date: 2020-11-03 Impact factor: 5.128
Authors: Sandra D Comer; Paolo Mannelli; Danesh Alam; Antoine Douaihy; Narinder Nangia; Sarah C Akerman; Abigail Zavod; Bernard L Silverman; Maria A Sullivan Journal: Am J Addict Date: 2020-04-04